IHCH-7113
IHCH-7113.svg
Identifiers
  • (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline
CAS Number
PubChem CID
Chemical and physical data
FormulaC14H19N3
Molar mass229.327 g·mol−1
3D model (JSmol)
  • CN1CCN2[C@H]3CCNC[C@H]3C4=C2C1=CC=C4
  • InChI=1S/C14H19N3/c1-16-7-8-17-12-5-6-15-9-11(12)10-3-2-4-13(16)14(10)17/h2-4,11-12,15H,5-9H2,1H3/t11-,12-/m0/s1
  • Key:QLGUCSLWLPCOTR-RYUDHWBXSA-N

IHCH-7113 is a drug which acts as an agonist at the 5-HT2A serotonin receptor. It was derived by structural simplification of the 5-HT2A antagonist atypical antipsychotic drug lumateperone along with several related compounds such as IHCH-7079 and IHCH-7086, which were found to be nonhallucinogenic biased 5-HT2A agonists that were active in antidepressant assays but did not produce psychedelic-like responding in mice. IHCH-7113 however produced a head-twitch response comparable to that of DOI or LSD, which was blocked by the 5-HT2A antagonist MDL100907.[1][2][3]

See also

References

  1. ^ Robichaud AJ, et al. Substituted heterocycle fused gamma-carbolines. Patent US 6552017
  2. ^ Tomesch JC, et al. Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof. Patent US 9315504]
  3. ^ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. doi:10.1126/science.abl8615. PMID 35084960.